AI Impact on Oligonucleotides Market - BCC Pulse Report

Report Highlights

This report provides an outlook of artificial intelligence (AI) impact on the global oligonucleotides market. It highlights major adoption trends of AI and machine learning (ML)-based algorithms across the key geographic regions from North America to the Asia-Pacific and Europe. The report covers disruptions caused across several key industry verticals and the impact on the various stages of the value chain analysis.

Report Includes

• Impact analysis of artificial intelligence (AI) on the global oligonucleotides market landscape
• Case studies for successful integration of AI and machine learning (ML)-based algorithms in for enzymatic oligonucleotide synthesis, patient care and accelerated oligonucleotide drug development
• Highlights of AI adoption trends across the major geographical regions as well as disruptions caused by AI across key industry verticals
• Review of AI impact on the various stages of the global supply chain analysis
• Competitive landscape featuring strategic initiatives, market spendings and venture funding outlook

Report Scope

Artificial intelligence (AI) is transforming the field of oligonucleotide therapy by revolutionizing drug discovery, target identification and manufacturing procedures. AI tools analyze large datasets, identify potential genetic targets and predict the outcomes of oligonucleotide therapeutics. AI plays a significant role in identifying patient-specific genetic variations that may influence treatment outcomes. AI models can also be used to gather real-world evidence and monitor the long-term effects of oligonucleotide therapy.

Many companies in the U.S., such as Amgen Inc., Alnylam Pharmaceuticals Inc. and Eli Lilly, are utilizing AI-based technologies for drug discovery, manufacturing operations and the optimization of clinical trials.